Pre-clinical and clinical studies on dimebon (dimebolin or latrepirdine) have demonstrated its use as a cognitive enhancer. Here, we show that dimebon administered to 3-month-old C57BL6N mice 15 min prior to training in both appetitive and inhibitory learning tasks via repeated (0.1 mg/kg) and acute (0.5 mg/kg) i.p. injections, respectively, increases memory scores. Acute treatment with dimebon was found to enhance inhibitory learning, as also shown in the step-down avoidance paradigm in 7-month-old mice. Bolus administration of dimebon did not affect the animals' locomotion, exploration or anxiety-like behaviour, with the exception of exploratory behaviour in older mice in the novel cage test. In a model of appetitive learning, a spatial version of the Y-maze, dimebon increased the rate of correct choices and decreased the latency of accessing a water reward after water deprivation, and increased the duration of drinking behaviour during training/testing procedures. Repeated treatment with dimebon did not alter the behaviours in other tests or water consumption. Acute treatment of water-deprived and non-water-deprived mice with dimebon also did not affect their water intake. Our data suggest that dimebon enhances hippocampus-dependent learning in both appetitive and inhibitory tasks in mice.
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Introduction
Dimebon is a candidate for therapeutics against Alzheimer's disease, and its clinical activity is currently under investigation. It was originally developed in 1983 in Russia where it was used as an antihistamine. Ongoing clinical trials are re-assessing contradictory results (Miller, 2010) concerning the previously shown efficacy of dimebon in the improvement of thinking processes and functioning in patients with mild to moderate Alzheimer's disease (Bachurin et al., 2001; Doody et al., 2008; O'Brien, 2008; Gura, 2008) and its curative effects in patients with Huntington's disease (Kieburtz et al., 2010) , also during co-application with other therapeutics. Evaluation of dimebon against a set of biochemical targets indicated that dimebon inhibits alpha-adrenergic receptors (alpha1A, alpha1B, and alpha1D, and alpha2A, alpha 2B, and alpha 2C), histamine H1 and H2 receptors and serotonin receptors (5-HT-2A, 5-HT2B, 5-HT2C, 5-HT5A, 5-HT6, and 5-HT7), dopamine receptors (D, D2S, and D3), and imidazoline I2 receptors (Schaffhauser et al., 2009; Giorgetti et al., 2010) . At low concentrations, dimebon potentiates the activity of AMPA-receptors and blocks NMDA-receptors in neurons (Grigorev et al., 2003) .
Pre-clinical studies revealed a number of activities of dimebon in in vitro and in vivo assays. Dimebon prevents the opening of mitochondrial pores induced by neurotoxins, which is regarded as the major pathogenetic factor of neurodegeneration (Bachurin et al., 2003; Hung, 2008) , elevates extracellular levels of amyloid beta in cell culture and the hippocampus of freely moving Tg2576 mice (Steele et al., 2009) , promotes neurite outgrowth in cultured hippocampal and cortical neurons (Protter et al., 2009; Bernales et al., 2009) , and enhances hippocampal neurogenesis (Pieper et al., 2010) .
Bolus administration of dimebon in rats resulted in enhancement of short-term learning in the social recognition paradigm (10 mg/kg, i.p.;
